SGLT2 inhibitors, NSAIDs, budesonide-formoterol reliever therapy and medication review in RACFs
A systematic review of 4 studies provides substantiveevidence supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes. SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death due to kidney disease. SGLT2 inhibitors also reduced end-stage kidney disease by 35% and acute kidney injury by 25%.
Lancet Diabetes & Endocrinology, published 5 September 2019.
This longitudinal study from Canada suggests that NSAID use contributes substantially to an increased risk of cardiovascular disease (CVD) among patients with osteoarthritis. Approximately 41% of the total effect of OA on increased CVD risk was mediated through NSAIDs.
Arthritis & Rheumatology, first published 6 August 2019.
Results from a 52-week open-label RCT show budesonide–formoterol used as needed for symptom relief is more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline in adults with mild to moderate asthma.
Lancet, published 23 August 2019.
A systematic review of stand‐alone medication review or reconciliation interventions in Australian RACFs identified an average of 2.7‐3.9 medication‐related problems (MRPs) per resident. Three studies reported general practitioners’ acceptance of pharmacists’ recommendations to resolve MRPs, ranging between 45 and 84%. This highlights the value of pharmacists and GPs working together to optimise medication management in this setting.
Australasian Journal on Ageing 2019;38 (suppl 2):9-25.